Your browser doesn't support javascript.
loading
A prospective multicenter trial of peripheral blood stem cell sibling allografts for acute myeloid leukemia in first complete remission using fludarabine-cyclophosphamide reduced intensity conditioning.
Grigg, A P; Gibson, J; Bardy, P G; Reynolds, J; Shuttleworth, P; Koelmeyer, R L; Szer, J; Roberts, A W; To, L B; Kennedy, G; Bradstock, K F.
Afiliación
  • Grigg AP; Department of Clinical Haematology and Bone Marrow Transplant Service, Royal Melbourne Hospital, Melbourne, Australia. andrew.grigg@mh.org.au
Biol Blood Marrow Transplant ; 13(5): 560-7, 2007 May.
Article en En | MEDLINE | ID: mdl-17448915
The role of allogeneic transplantation in patients with de novo acute myeloid leukemia in first complete remission (AML-CR1) is controversial. Aiming to preserve a graft-versus-leukemia effect, but minimize morbidity and mortality from conditioning-related toxicity and graft-versus-host disease (GVHD), we conducted a prospective multicenter study of reduced-intensity conditioning (RIC) as preparation for peripheral blood stem cell sibling allografts in patients with intermediate or poor risk AML-CR1. Conditioning consisted of fludarabine 125 mg/m(2) and cyclophosphamide 120 mg/kg. Thirty-four patients were transplanted with a median age of 45 years; 85% had intermediate risk cytogenetics. Early toxicity was minimal. The overall incidence of grade II-IV acute GVHD was low (21%), but the 3 patients (9%) who developed grade IV GVHD died. Donor T cell chimerism was rapid and generally complete, but complete myeloid chimerism was delayed. Thirteen patients (38%) relapsed, 12 within a year of transplant. The estimated disease-free survival (DFS) and overall survival at 2 years was 56% (95% confidence interval [CI] 39%-71%) and 68% (95% CI 50%-81%), respectively. The incidence of extensive chronic GVHD (cGVHD) was low (24% of surviving patients at 12 months) and most survivors had an excellent performance status. These observations justify a prospective comparison of RIC versus myeloablative conditioning allografts for AML-CR1.
Asunto(s)
Buscar en Google
Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Leucemia Mieloide / Enfermedad Aguda / Trasplante de Células Madre Hematopoyéticas / Acondicionamiento Pretrasplante / Trasplante de Células Madre de Sangre Periférica Tipo de estudio: Clinical_trials / Observational_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Biol Blood Marrow Transplant Asunto de la revista: HEMATOLOGIA / TRANSPLANTE Año: 2007 Tipo del documento: Article País de afiliación: Australia Pais de publicación: Estados Unidos
Buscar en Google
Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Leucemia Mieloide / Enfermedad Aguda / Trasplante de Células Madre Hematopoyéticas / Acondicionamiento Pretrasplante / Trasplante de Células Madre de Sangre Periférica Tipo de estudio: Clinical_trials / Observational_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Biol Blood Marrow Transplant Asunto de la revista: HEMATOLOGIA / TRANSPLANTE Año: 2007 Tipo del documento: Article País de afiliación: Australia Pais de publicación: Estados Unidos